European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas.
Identifieur interne : 000C82 ( PubMed/Checkpoint ); précédent : 000C81; suivant : 000C83European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas.
Auteurs : Gerald Raverot [France] ; Pia Burman [Suède] ; Ann I. Mccormack [Australie] ; A P Heaney [États-Unis] ; Stephan Petersenn [Allemagne] ; Vera Popovic [Serbie] ; Jacqueline Trouillas [France] ; Olaf Dekkers [Pays-Bas]Source :
- European journal of endocrinology [ 1479-683X ] ; 2017.
Abstract
Pituitary tumours are common and easily treated by surgery or medical treatment in most cases. However, a small subset of pituitary tumours does not respond to standard medical treatment and presents with multiple local recurrences (aggressive pituitary tumours) and in rare occasion with metastases (pituitary carcinoma). The present ESE guideline aims to provide clinical guidance on diagnosis, treatment and follow-up in aggressive pituitary tumours and carcinomas.
DOI: 10.1530/EJE-17-0796
PubMed: 29046323
Affiliations:
- Allemagne, Australie, France, Pays-Bas, Serbie, Suède, États-Unis
- Auvergne-Rhône-Alpes, Californie, Hambourg, Hollande-Méridionale, Rhône-Alpes
- Hambourg, Leyde, Los Angeles, Lyon
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:29046323Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas.</title><author><name sortKey="Raverot, Gerald" sort="Raverot, Gerald" uniqKey="Raverot G" first="Gerald" last="Raverot">Gerald Raverot</name><affiliation wicri:level="1"><nlm:affiliation>G Raverot, Federation d'endocrinologie, Hospices civils de Lyon, bron, France gerald.raverot@chu-lyon.fr.</nlm:affiliation><country wicri:rule="url">France</country><wicri:regionArea>G Raverot, Federation d'endocrinologie, Hospices civils de Lyon, bron</wicri:regionArea><wicri:noRegion>bron</wicri:noRegion><wicri:noRegion>bron</wicri:noRegion></affiliation></author><author><name sortKey="Burman, Pia" sort="Burman, Pia" uniqKey="Burman P" first="Pia" last="Burman">Pia Burman</name><affiliation wicri:level="1"><nlm:affiliation>P Burman, Department of Endocrinology, Skånes University Hospital, Malmö, SE-20502, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>P Burman, Department of Endocrinology, Skånes University Hospital, Malmö, SE-20502</wicri:regionArea><wicri:noRegion>SE-20502</wicri:noRegion></affiliation></author><author><name sortKey="Mccormack, Ann I" sort="Mccormack, Ann I" uniqKey="Mccormack A" first="Ann I" last="Mccormack">Ann I. Mccormack</name><affiliation wicri:level="1"><nlm:affiliation>A McCormack, Department of Endocrinology, St Vincent's Hospital, Sydney, 2010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>A McCormack, Department of Endocrinology, St Vincent's Hospital, Sydney, 2010</wicri:regionArea><wicri:noRegion>2010</wicri:noRegion></affiliation></author><author><name sortKey="Heaney, A P" sort="Heaney, A P" uniqKey="Heaney A" first="A P" last="Heaney">A P Heaney</name><affiliation wicri:level="3"><nlm:affiliation>A Heaney, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>A Heaney, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles</wicri:regionArea><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Petersenn, Stephan" sort="Petersenn, Stephan" uniqKey="Petersenn S" first="Stephan" last="Petersenn">Stephan Petersenn</name><affiliation wicri:level="3"><nlm:affiliation>S Petersenn, ENDOC , Center for Endocrine Tumors, Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>S Petersenn, ENDOC , Center for Endocrine Tumors, Hamburg</wicri:regionArea><placeName><settlement type="city">Hambourg</settlement><region type="land" nuts="2">Hambourg</region></placeName></affiliation></author><author><name sortKey="Popovic, Vera" sort="Popovic, Vera" uniqKey="Popovic V" first="Vera" last="Popovic">Vera Popovic</name><affiliation wicri:level="1"><nlm:affiliation>V Popovic, University of Belgrade, School of Medicine, Belgrade, Serbia.</nlm:affiliation><country xml:lang="fr">Serbie</country><wicri:regionArea>V Popovic, University of Belgrade, School of Medicine, Belgrade</wicri:regionArea><wicri:noRegion>Belgrade</wicri:noRegion></affiliation></author><author><name sortKey="Trouillas, Jacqueline" sort="Trouillas, Jacqueline" uniqKey="Trouillas J" first="Jacqueline" last="Trouillas">Jacqueline Trouillas</name><affiliation wicri:level="3"><nlm:affiliation>J Trouillas, Faculté de Médecine, Universite Claude Bernard Lyon 1 - Domaine de Rockefeller, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>J Trouillas, Faculté de Médecine, Universite Claude Bernard Lyon 1 - Domaine de Rockefeller, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Dekkers, Olaf" sort="Dekkers, Olaf" uniqKey="Dekkers O" first="Olaf" last="Dekkers">Olaf Dekkers</name><affiliation wicri:level="3"><nlm:affiliation>O Dekkers, Departments of Internal Medicine (section Endocrinology) & Clinical Epidemiology, Leids Universitair Medisch Centrum Centrum voor Humane en Klinische Genetica, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>O Dekkers, Departments of Internal Medicine (section Endocrinology) & Clinical Epidemiology, Leids Universitair Medisch Centrum Centrum voor Humane en Klinische Genetica, Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:29046323</idno><idno type="pmid">29046323</idno><idno type="doi">10.1530/EJE-17-0796</idno><idno type="wicri:Area/PubMed/Corpus">000367</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000367</idno><idno type="wicri:Area/PubMed/Curation">000365</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000365</idno><idno type="wicri:Area/PubMed/Checkpoint">000365</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000365</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas.</title><author><name sortKey="Raverot, Gerald" sort="Raverot, Gerald" uniqKey="Raverot G" first="Gerald" last="Raverot">Gerald Raverot</name><affiliation wicri:level="1"><nlm:affiliation>G Raverot, Federation d'endocrinologie, Hospices civils de Lyon, bron, France gerald.raverot@chu-lyon.fr.</nlm:affiliation><country wicri:rule="url">France</country><wicri:regionArea>G Raverot, Federation d'endocrinologie, Hospices civils de Lyon, bron</wicri:regionArea><wicri:noRegion>bron</wicri:noRegion><wicri:noRegion>bron</wicri:noRegion></affiliation></author><author><name sortKey="Burman, Pia" sort="Burman, Pia" uniqKey="Burman P" first="Pia" last="Burman">Pia Burman</name><affiliation wicri:level="1"><nlm:affiliation>P Burman, Department of Endocrinology, Skånes University Hospital, Malmö, SE-20502, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>P Burman, Department of Endocrinology, Skånes University Hospital, Malmö, SE-20502</wicri:regionArea><wicri:noRegion>SE-20502</wicri:noRegion></affiliation></author><author><name sortKey="Mccormack, Ann I" sort="Mccormack, Ann I" uniqKey="Mccormack A" first="Ann I" last="Mccormack">Ann I. Mccormack</name><affiliation wicri:level="1"><nlm:affiliation>A McCormack, Department of Endocrinology, St Vincent's Hospital, Sydney, 2010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>A McCormack, Department of Endocrinology, St Vincent's Hospital, Sydney, 2010</wicri:regionArea><wicri:noRegion>2010</wicri:noRegion></affiliation></author><author><name sortKey="Heaney, A P" sort="Heaney, A P" uniqKey="Heaney A" first="A P" last="Heaney">A P Heaney</name><affiliation wicri:level="3"><nlm:affiliation>A Heaney, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>A Heaney, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles</wicri:regionArea><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Petersenn, Stephan" sort="Petersenn, Stephan" uniqKey="Petersenn S" first="Stephan" last="Petersenn">Stephan Petersenn</name><affiliation wicri:level="3"><nlm:affiliation>S Petersenn, ENDOC , Center for Endocrine Tumors, Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>S Petersenn, ENDOC , Center for Endocrine Tumors, Hamburg</wicri:regionArea><placeName><settlement type="city">Hambourg</settlement><region type="land" nuts="2">Hambourg</region></placeName></affiliation></author><author><name sortKey="Popovic, Vera" sort="Popovic, Vera" uniqKey="Popovic V" first="Vera" last="Popovic">Vera Popovic</name><affiliation wicri:level="1"><nlm:affiliation>V Popovic, University of Belgrade, School of Medicine, Belgrade, Serbia.</nlm:affiliation><country xml:lang="fr">Serbie</country><wicri:regionArea>V Popovic, University of Belgrade, School of Medicine, Belgrade</wicri:regionArea><wicri:noRegion>Belgrade</wicri:noRegion></affiliation></author><author><name sortKey="Trouillas, Jacqueline" sort="Trouillas, Jacqueline" uniqKey="Trouillas J" first="Jacqueline" last="Trouillas">Jacqueline Trouillas</name><affiliation wicri:level="3"><nlm:affiliation>J Trouillas, Faculté de Médecine, Universite Claude Bernard Lyon 1 - Domaine de Rockefeller, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>J Trouillas, Faculté de Médecine, Universite Claude Bernard Lyon 1 - Domaine de Rockefeller, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Dekkers, Olaf" sort="Dekkers, Olaf" uniqKey="Dekkers O" first="Olaf" last="Dekkers">Olaf Dekkers</name><affiliation wicri:level="3"><nlm:affiliation>O Dekkers, Departments of Internal Medicine (section Endocrinology) & Clinical Epidemiology, Leids Universitair Medisch Centrum Centrum voor Humane en Klinische Genetica, Leiden, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>O Dekkers, Departments of Internal Medicine (section Endocrinology) & Clinical Epidemiology, Leids Universitair Medisch Centrum Centrum voor Humane en Klinische Genetica, Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author></analytic><series><title level="j">European journal of endocrinology</title><idno type="eISSN">1479-683X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pituitary tumours are common and easily treated by surgery or medical treatment in most cases. However, a small subset of pituitary tumours does not respond to standard medical treatment and presents with multiple local recurrences (aggressive pituitary tumours) and in rare occasion with metastases (pituitary carcinoma). The present ESE guideline aims to provide clinical guidance on diagnosis, treatment and follow-up in aggressive pituitary tumours and carcinomas.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">29046323</PMID><DateCreated><Year>2017</Year><Month>10</Month><Day>19</Day></DateCreated><DateRevised><Year>2017</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1479-683X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2017</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>European journal of endocrinology</Title><ISOAbbreviation>Eur. J. Endocrinol.</ISOAbbreviation></Journal><ArticleTitle>European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">EJE-17-0796</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1530/EJE-17-0796</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pituitary tumours are common and easily treated by surgery or medical treatment in most cases. However, a small subset of pituitary tumours does not respond to standard medical treatment and presents with multiple local recurrences (aggressive pituitary tumours) and in rare occasion with metastases (pituitary carcinoma). The present ESE guideline aims to provide clinical guidance on diagnosis, treatment and follow-up in aggressive pituitary tumours and carcinomas.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We decided upfront, while acknowledging literature on aggressive pituitary tumours and carcinomas is scarce, to systematically review the literature according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. The review focused primarily on first and second line treatment in aggressive pituitary tumours and carcinomas. We included 14 single arm cohort studies (total number of patients = 116) most on temozolomide treatment (n=11 studies, total number of patients = 106). A positive treatment effect was seen in 47% (95% CI 36-58%) of temozolomide treated. Data from the recently performed ESE survey on aggressive pituitary tumours and carcinomas (165 patients) was also used as backbone for the guideline. Selected recommendation: (i) Patients with aggressive pituitary tumours should be managed by a multidisciplinary expert team. (ii) Histopathological analysis including pituitary hormones and proliferative markers are needed for correct tumour classification. (iii) Temozolomide monotherapy is the first line chemotherapy for aggressive pituitary tumours and pituitary carcinomas after failure of standard therapies; treatment evaluation after 3 cycles allows identification of responder and non-responders patients. (iv) In patients responding to first line temozolomide, we suggest continuing treatment for at least 6 months in total. Furthermore, the guideline offers recommendations for patients who recurred after temozolomide treatment, for those who did not respond to temozolomide, for patients with systemic metastasis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raverot</LastName><ForeName>Gerald</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>G Raverot, Federation d'endocrinologie, Hospices civils de Lyon, bron, France gerald.raverot@chu-lyon.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burman</LastName><ForeName>Pia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>P Burman, Department of Endocrinology, Skånes University Hospital, Malmö, SE-20502, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCormack</LastName><ForeName>Ann I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>A McCormack, Department of Endocrinology, St Vincent's Hospital, Sydney, 2010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heaney</LastName><ForeName>A P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>A Heaney, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersenn</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>S Petersenn, ENDOC , Center for Endocrine Tumors, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popovic</LastName><ForeName>Vera</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>V Popovic, University of Belgrade, School of Medicine, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trouillas</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>J Trouillas, Faculté de Médecine, Universite Claude Bernard Lyon 1 - Domaine de Rockefeller, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dekkers</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>O Dekkers, Departments of Internal Medicine (section Endocrinology) & Clinical Epidemiology, Leids Universitair Medisch Centrum Centrum voor Humane en Klinische Genetica, Leiden, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Endocrinol</MedlineTA><NlmUniqueID>9423848</NlmUniqueID><ISSNLinking>0804-4643</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29046323</ArticleId><ArticleId IdType="pii">EJE-17-0796</ArticleId><ArticleId IdType="doi">10.1530/EJE-17-0796</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>Pays-Bas</li><li>Serbie</li><li>Suède</li><li>États-Unis</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Californie</li><li>Hambourg</li><li>Hollande-Méridionale</li><li>Rhône-Alpes</li></region><settlement><li>Hambourg</li><li>Leyde</li><li>Los Angeles</li><li>Lyon</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Raverot, Gerald" sort="Raverot, Gerald" uniqKey="Raverot G" first="Gerald" last="Raverot">Gerald Raverot</name></noRegion><name sortKey="Trouillas, Jacqueline" sort="Trouillas, Jacqueline" uniqKey="Trouillas J" first="Jacqueline" last="Trouillas">Jacqueline Trouillas</name></country><country name="Suède"><noRegion><name sortKey="Burman, Pia" sort="Burman, Pia" uniqKey="Burman P" first="Pia" last="Burman">Pia Burman</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Mccormack, Ann I" sort="Mccormack, Ann I" uniqKey="Mccormack A" first="Ann I" last="Mccormack">Ann I. Mccormack</name></noRegion></country><country name="États-Unis"><region name="Californie"><name sortKey="Heaney, A P" sort="Heaney, A P" uniqKey="Heaney A" first="A P" last="Heaney">A P Heaney</name></region></country><country name="Allemagne"><region name="Hambourg"><name sortKey="Petersenn, Stephan" sort="Petersenn, Stephan" uniqKey="Petersenn S" first="Stephan" last="Petersenn">Stephan Petersenn</name></region></country><country name="Serbie"><noRegion><name sortKey="Popovic, Vera" sort="Popovic, Vera" uniqKey="Popovic V" first="Vera" last="Popovic">Vera Popovic</name></noRegion></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Dekkers, Olaf" sort="Dekkers, Olaf" uniqKey="Dekkers O" first="Olaf" last="Dekkers">Olaf Dekkers</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C82 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000C82 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:29046323
|texte= European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:29046323" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |